Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute (SCRI), shared a post on LinkedIn:
“Hot off the press! Thrilled to share our latest publication in Nature Portfolio NPJ Precision Oncology
- “A unified framework for pre-screening and screening tools in oncology clinical trials”
- Delighted to collaborate with Denis Horgan, Ph.D Arturo LoAIza-Bonilla MD et al. on this paper.
- Clinical trial enrollment faces mounting challenges-complex eligibility criteria, biomarker stratification, fragmented data.
- We review the landscape from manual workflows to AI-enabled approaches, examining how LLMs and hybrid frameworks can improve matching efficiency, and access to investigational therapies”
Title: A unified framework for pre-screening and screening tools in oncology clinical trials
Authors: Denis Horgan, Joe Paulson, Arturo Loaiza-Bonilla, Christer Svedman, Umberto Malapelle, Frédérique Penault Lorca, Hadi Mohamad Abu Rahsheed, Paul Hofman, Stan Kachnowsk, Daniel Schneider and Vivek Subbiah
Read the full paper.
More posts featuring Vivek Subbiah.